Structure	Catalog	Product Name	CAS	E3 Ligase	Target	Inquiry
	BPL-201853	3-(5-(4-(2-((1-(5-((1R,3R)-2-(2-Fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)pyrimidin-2-yl)piperidin-4-yl)oxy)ethyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione	2500656-42-6	CRBN	ER	Inquiry
Molecular Weight: 791.97 Molecular Formula: C44H54FN9O4 Density: 1.37±0.1 g/cm3 Description: It is a PROTAC that degrades estrogen receptor (ER) for the treatment of breast cancer.
	BPL-201854	3-(5-(4-(5-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenoxy)pentyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione	2500656-43-7	CRBN	ER	Inquiry
Molecular Weight: 784.92 Molecular Formula: C44H51F3N6O4 Boiling Point: 897.9±65.0°C at 760 Torr Density: 1.280±0.06 g/cm3 Description: It is a PROTAC that degrades estrogen receptor (ER) for the treatment of breast cancer.
	BPL-201855	3-(5-(4-((4-((1-(5-((1R,3R)-2-(2-Fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)pyrimidin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)methyl)piperidin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione	2500656-44-8	CRBN	ER	Inquiry
Molecular Weight: 859.11 Molecular Formula: C49H63FN10O3 Density: 1.259±0.06 g/cm3 Description: It is a PROTAC that degrades estrogen receptor (ER) for the treatment of breast cancer.
	BPL-201856	3-(5-(4-(2-(9-(5-((1R,3R)-2-(2-Fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)pyrimidin-2-yl)-3,9-diazaspiro[5.5]undecan-3-yl)ethyl)piperidin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione	2500656-49-3	CRBN	ER	Inquiry
Molecular Weight: 844.09 Molecular Formula: C49H62FN9O3 Density: 1.34±0.1 g/cm3 Description: It is a PROTAC that degrades estrogen receptor (ER) for the treatment of breast cancer.
	BPL-201857	3-(5-(9-(2-(1-(5-((1R,3R)-2-(2-Fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)pyrimidin-2-yl)piperidin-4-yl)ethyl)-3,9-diazaspiro[5.5]undecan-3-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione	2500656-50-6	CRBN	ER	Inquiry
Molecular Weight: 844.09 Molecular Formula: C49H62FN9O3 Density: 1.34±0.1 g/cm3 Description: It is a PROTAC that degrades estrogen receptor (ER) for the treatment of breast cancer.
	BPL-201858	3-(5-(4-(2-(1-(5-((1R,3R)-2-(2-Fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)pyrimidin-2-yl)piperidin-4-yl)ethyl)piperazin-1-yl)-7-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione	2500656-51-7	CRBN	ER	Inquiry
Molecular Weight: 805.98 Molecular Formula: C45H56FN9O4 Density: 1.269±0.06 g/cm3 Description: It is a PROTAC that degrades estrogen receptor (ER) for the treatment of breast cancer.
	BPL-201859	3-(5-(10-((1-(5-((1R,3R)-2-(2-Fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)pyrimidin-2-yl)piperidin-4-yl)methyl)-7-oxa-3,10-diazaspiro[5.6]dodecan-3-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione	2500656-58-4	CRBN	ER	Inquiry
Molecular Weight: 846.07 Molecular Formula: C48H60FN9O4 Density: 1.36±0.1 g/cm3 Description: It is a PROTAC that degrades estrogen receptor (ER) for the treatment of breast cancer.
	BPL-201860	3-(5-(10-(2-(1-(5-((1R,3R)-2-(2-Fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)pyrimidin-2-yl)piperidin-4-yl)ethyl)-7-oxa-3,10-diazaspiro[5.6]dodecan-3-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione	2500656-59-5	CRBN	ER	Inquiry
Molecular Weight: 860.09 Molecular Formula: C49H62FN9O4 Density: 1.35±0.1 g/cm3 Description: It is a PROTAC that degrades estrogen receptor (ER) for the treatment of breast cancer.
	BPL-201861	3-(5-(2-((7-(5-((1R,3R)-2-(2-Fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)pyrimidin-2-yl)-7-azaspiro[3.5]nonan-2-yl)methyl)-2,7-diazaspiro[3.5]nonan-7-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione	2500656-67-5	CRBN	ER	Inquiry
Molecular Weight: 842.08 Molecular Formula: C49H60FN9O3 Density: 1.37±0.1 g/cm3 Description: It is a PROTAC that degrades estrogen receptor (ER) for the treatment of breast cancer.
	BPL-201862	3-(5-(4-((1-(5-((1R,3R)-2-(2-Fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)pyrimidin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)-7-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione	2500656-78-8	CRBN	ER	Inquiry
Molecular Weight: 791.97 Molecular Formula: C44H54FN9O4 Density: 1.287±0.06 g/cm3 Description: It is a PROTAC that degrades estrogen receptor (ER) for the treatment of breast cancer.
	BPL-201863	3-(5-(4-((9-((5-((1R,3R)-2-(2-Fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)pyrimidin-2-yl)oxy)-3-azaspiro[5.5]undecan-3-yl)methyl)piperidin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione	2500656-80-2	CRBN	ER	Inquiry
Molecular Weight: 845.08 Molecular Formula: C49H61FN8O4 Density: 1.34±0.1 g/cm3 Description: It is a PROTAC that degrades estrogen receptor (ER) for the treatment of breast cancer.
	BPL-201864	(2S,4R)-N-(2-(4-(2-(4-(3-Amino-6-(2-hydroxyphenyl)pyridazin-4-yl)piperazin-1-yl)ethoxy)phenethoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide	2416415-18-2	VHL	SMARCA2 SMARCA4	Inquiry
Molecular Weight: 950.15 Molecular Formula: C50H60FN9O7S Boiling Point: 1163.8±65.0°C at 760 Torr Density: 1.39±0.1 g/cm3 Description: It is a SMARCA2/4 PROTAC used to target protein degradation and cancer therapy.
	BPL-201865	(2S,4R)-N-(2-(3-(4-((4-(3-Amino-6-(2-hydroxyphenyl)pyridazin-4-yl)piperazin-1-yl)methyl)phenoxy)propoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide	2416415-19-3	VHL	SMARCA2 SMARCA4	Inquiry
Molecular Weight: 950.15 Molecular Formula: C50H60FN9O7S Boiling Point: 1136.9±65.0°C at 760 Torr Density: 1.39±0.1 g/cm3 Description: It is a SMARCA2/4 PROTAC used to target protein degradation and cancer therapy.
	BPL-201866	(2S,4R)-N-(2-(3-(4-((4-(3-Amino-6-(2-hydroxyphenyl)pyridazin-4-yl)piperazin-1-yl)methyl)phenyl)propoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide	2416415-22-8	VHL	SMARCA2 SMARCA4	Inquiry
Molecular Weight: 934.15 Molecular Formula: C50H60FN9O6S Boiling Point: 1135.7±65.0°C at 760 Torr Density: 1.38±0.1 g/cm3 Description: It is a SMARCA2/4 PROTAC used to target protein degradation and cancer therapy.
	BPL-201867	(2S,4R)-N-(2-(4-((4-(3-Amino-6-(2-hydroxyphenyl)pyridazin-4-yl)piperazin-1-yl)methyl)-3-fluorophenethoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide	2416415-24-0	VHL	SMARCA2 SMARCA4	Inquiry
Molecular Weight: 938.12 Molecular Formula: C49H57F2N9O6S Boiling Point: 1127.3±65.0°C at 760 Torr Density: 1.41±0.1 g/cm3 Description: It is a SMARCA2/4 PROTAC used to target protein degradation and cancer therapy.
	BPL-201868	N-(3-((2-((4-(Cyanomethyl)phenyl)amino)-6-((4,5-dimethyl-1H-pyrazol-3-yl)amino)pyrimidin-4-yl)amino)propyl)-7-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)heptanamide	2769860-16-2	CRBN	GSK3A GSK-3beta	Inquiry
Molecular Weight: 832.92 Molecular Formula: C42H48N12O7 Density: 1.383±0.06 g/cm3 Description: It is a multi-targeted degrader, and kinase degradation is dependent on p97.
	BPL-201869	N-(3-((2-((4-(Cyanomethyl)phenyl)amino)-6-((4-ethyl-1H-pyrazol-3-yl)amino)pyrimidin-4-yl)amino)propyl)-7-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)heptanamide	2769859-97-2	CRBN	GSK3A GSK-3beta	Inquiry
Molecular Weight: 832.92 Molecular Formula: C42H48N12O7 Density: 1.383±0.06 g/cm3 Description: It is a multi-targeted degrader, and kinase degradation is dependent on p97.
	BPL-201870	N1-(3-((2-((4-(Cyanomethyl)phenyl)amino)-6-((5-cyclopropyl-1H-pyrazol-3-yl)amino)pyrimidin-4-yl)amino)propyl)-N9-((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)nonanediamide	2769859-51-8	VHL	AAK1 AURKA AURKB BMP2K CDK9 EPHB2 GSK-3beta ITK LATS1 MAP4K2 NEK9 PAK4 PLK4 STK17B	Inquiry
Molecular Weight: 1000.29 Molecular Formula: C53H69N13O5S Density: 1.290±0.06 g/cm3 Description: It is a multi-targeted degrader, and kinase degradation is dependent on p97.
	BPL-201871	(2S,4R)-1-((S)-2-(9-((S)-3-((2-Chloro-5-(2,2-difluoroethyl)-8-fluoro-5H-dibenzo[b,e][1,4]diazepin-11-yl)amino)pyrrolidin-1-yl)-9-oxononanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide	2769859-31-4	VHL	PAK1	Inquiry
Molecular Weight: 991.62 Molecular Formula: C51H62ClF3N8O5S Boiling Point: 1136.7±65.0°C at 760 Torr Density: 1.36±0.1 g/cm3 Description: It is a multi-targeted degrader, and kinase degradation is dependent on p97.
	BPL-201872	4-((4-(4-(4-(5-Chloro-4-(1-oxo-2,8-diazaspiro[4.5]decan-8-yl)pyridin-3-yl)phenyl)-1H-pyrazol-1-yl)butyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione	2139348-68-6	CRBN	CDK19 CDK8	Inquiry
Molecular Weight: 735.25 Molecular Formula: C39H39ClN8O5 Boiling Point: 1041.4±65.0°C at 760 Torr Density: 1.50±0.1 g/cm3 Description: It is a multi-targeted degrader, and kinase degradation is dependent on p97.

PROTAC Library